target,target_id,target_uniprot,target_species,ligand,ligand_id,ligand_species,ligand_pubchem_cid,smiles,inchi,inchikey,type,action,action_comment,endogenous,primary_target,concentration_range,affinity_parameter,affinity_high,affinity_median,affinity_low,original_affinity_units,original_affinity_low_nm,original_affinity_median_nm,original_affinity_high_nm,original_affinity_relation,assay_description,receptor_site,ligand_context,pubmed_id GluN2A,456,Q12879,Human,Mg2+,708,,888,,,,Channel blocker,None,GluN2A = GluN2B > GluN2C = GluN2D,,,,,,,,,,,,=,,,,, GluN2A,456,Q12879,Human,glycine,727,,750,NCC(=O)O,"InChI=1S/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)",DHMQDGOQFOQNFH-UHFFFAOYSA-N,Agonist,Agonist,GluN2D > GluN2C > GluN2B > GluN2A,yes,,,,,,,,,,,=,,glycine site,,, GluN2A,456,Q12879,Human,"5,7-dichlorokynurenic acid",2361,,1779,Clc1cc(Cl)c2c(c1)[nH]c(cc2=O)C(=O)O,"InChI=1S/C10H5Cl2NO3/c11-4-1-5(12)9-6(2-4)13-7(10(15)16)3-8(9)14/h1-3H,(H,13,14)(H,15,16)",BGKFPRIGXAVYNX-UHFFFAOYSA-N,Antagonist,Antagonist,,,,,,,,,,,,,=,,glycine site,,, GluN2A,456,Q12879,Human,dizocilpine,2403,,180081,C[C@]12N[C@@H](c3c2cccc3)Cc2c1cccc2,"InChI=1S/C16H15N/c1-16-13-8-4-2-6-11(13)10-15(17-16)12-7-3-5-9-14(12)16/h2-9,15,17H,10H2,1H3/t15-,16+/m1/s1",LBOJYSIDWZQNJS-CVEARBPZSA-N,Channel blocker,None,,,,,,,,,,,,,=,,,,, GluN2A,456,Q12879,Human,L-aspartic acid,3309,,5960,OC(=O)C[C@@H](C(=O)O)N,"InChI=1S/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)/t2-/m0/s1",CKLJMWTZIZZHCS-REOHCLBHSA-N,Agonist,Agonist,GluN2D = GluN2B > GluN2C = GluN2A,yes,,,,,,,,,,,=,,glutamate site,,, GluN2A,456,Q12879,Human,(+)-HA966,4066,,6603720,O=C1[C@H](N)CCN1O,"InChI=1S/C4H8N2O2/c5-3-1-2-6(8)4(3)7/h3,8H,1-2,5H2/t3-/m1/s1",HCKUBNLZMKAEIN-GSVOUGTGSA-N,Agonist,Partial agonist,GluN2B > GluN2A,,,,,,,,,,,,=,,glycine site,,, GluN2A,456,Q12879,Human,(RS)-(tetrazol-5-yl)glycine,4068,,126383,OC(=O)C(c1nnn[nH]1)N,"InChI=1S/C3H5N5O2/c4-1(3(9)10)2-5-7-8-6-2/h1H,4H2,(H,9,10)(H,5,6,7,8)",UKBRUIZWQZHXFL-UHFFFAOYSA-N,Agonist,Full agonist,GluN2D > GluN2C = GluN2B > GluN2A,,,,,,,,,,,,=,,glutamate site,,, GluN2A,456,Q12879,Human,[3H]CGP39653,4078,,114756,CCCC(=CC(C(=O)O)N)CP(=O)(O)O,"InChI=1S/C8H16NO5P/c1-2-3-6(5-15(12,13)14)4-7(9)8(10)11/h4,7H,2-3,5,9H2,1H3,(H,10,11)(H2,12,13,14)",ZEFQYTSQDVUMEU-UHFFFAOYSA-N,Antagonist,Antagonist,,,,,,,,,,,,,=,,glutamate site,,, GluN2A,456,Q12879,Human,[3H]CGP61594,4079,,10025114,[N-]=[N+]=Nc1ccc(cc1)CC(=O)NC1CC(Nc2c1c(Cl)cc(c2)Cl)C(=O)O,"InChI=1S/C18H15Cl2N5O3/c19-10-6-12(20)17-13(7-10)22-15(18(27)28)8-14(17)23-16(26)5-9-1-3-11(4-2-9)24-25-21/h1-4,6-7,14-15,22H,5,8H2,(H,23,26)(H,27,28)",OVAIIHUWSLJJPO-UHFFFAOYSA-N,Antagonist,Antagonist,[3H]CGP61594 is a photoaffinity ligand,,,,,,,,,,,,=,,glycine site,,, GluN2A,456,Q12879,Human,[3H]CGS19755,4080,,4324257,OC(=O)C1NCCC(C1)CP(=O)(O)O,"InChI=1S/C7H14NO5P/c9-7(10)6-3-5(1-2-8-6)4-14(11,12)13/h5-6,8H,1-4H2,(H,9,10)(H2,11,12,13)",LPMRCCNDNGONCD-UHFFFAOYSA-N,Antagonist,Antagonist,,,,,,,,,,,,,=,,glutamate site,,, GluN2A,456,Q12879,Human,[3H]CPP,4082,,1228,OC(=O)C1NCCN(C1)CCCP(=O)(O)O,"InChI=1S/C8H17N2O5P/c11-8(12)7-6-10(4-2-9-7)3-1-5-16(13,14)15/h7,9H,1-6H2,(H,11,12)(H2,13,14,15)",CUVGUPIVTLGRGI-UHFFFAOYSA-N,Antagonist,Antagonist,,,,,,,,,,,,,=,,glutamate site,,, GluN2A,456,Q12879,Human,[3H]glycine,4084,,750,NCC(=O)O,"InChI=1S/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)",DHMQDGOQFOQNFH-UHFFFAOYSA-N,Agonist,Agonist,,,,,,,,,,,,,=,,glycine site,,, GluN2A,456,Q12879,Human,[3H]L689560,4086,,121918,O=C(N[C@@H]1C[C@H](Nc2c1c(Cl)cc(c2)Cl)C(=O)O)Nc1ccccc1,"InChI=1S/C17H15Cl2N3O3/c18-9-6-11(19)15-12(7-9)21-14(16(23)24)8-13(15)22-17(25)20-10-4-2-1-3-5-10/h1-7,13-14,21H,8H2,(H,23,24)(H2,20,22,25)/t13-,14+/m1/s1",UCKHICKHGAOGAP-KGLIPLIRSA-N,Antagonist,Antagonist,,,,,,,,,,,,,=,,glycine site,,, GluN2A,456,Q12879,Human,[3H]MDL105519,4088,,4023,Clc1cc(Cl)c2c(c1)[nH]c(c2C=C(c1ccccc1)C(=O)O)C(=O)O,"InChI=1S/C18H11Cl2NO4/c19-10-6-13(20)15-12(16(18(24)25)21-14(15)7-10)8-11(17(22)23)9-4-2-1-3-5-9/h1-8,21H,(H,22,23)(H,24,25)",LPWVUDLZUVBQGP-UHFFFAOYSA-N,Antagonist,Antagonist,,,,,,,,,,,,,=,,glycine site,,, GluN2A,456,Q12879,Human,[3H]dizocilpine,4089,,1207,CC12NC(c3c2cccc3)Cc2c1cccc2,"InChI=1S/C16H15N/c1-16-13-8-4-2-6-11(13)10-15(17-16)12-7-3-5-9-14(12)16/h2-9,15,17H,10H2,1H3",LBOJYSIDWZQNJS-UHFFFAOYSA-N,Channel blocker,None,,,,,,,,,,,,,=,,cation channel,,, GluN2A,456,Q12879,Human,amantadine,4128,,2130,NC12CC3CC(C2)CC(C1)C3,"InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2",DKNWSYNQZKUICI-UHFFFAOYSA-N,Channel blocker,None,GluN2C = GluN2D ≥ GluN2B ≥ GluN2A,,yes,,,,,,,,,,=,,,,, GluN2A,456,Q12879,Human,CGP37849,4154,,5950212,C/C(=C\C(C(=O)O)N)/CP(=O)(O)O,"InChI=1S/C6H12NO5P/c1-4(3-13(10,11)12)2-5(7)6(8)9/h2,5H,3,7H2,1H3,(H,8,9)(H2,10,11,12)/b4-2+",BDYHNCZIGYIOGJ-DUXPYHPUSA-N,Antagonist,Antagonist,,,,,,,,,,,,,=,,glutamate site,,, GluN2A,456,Q12879,Human,selfotel,4155,,68736,OC(=O)[C@H]1NCC[C@H](C1)CP(=O)(O)O,"InChI=1S/C7H14NO5P/c9-7(10)6-3-5(1-2-8-6)4-14(11,12)13/h5-6,8H,1-4H2,(H,9,10)(H2,11,12,13)/t5-,6+/m1/s1",LPMRCCNDNGONCD-RITPCOANSA-N,Antagonist,Antagonist,,,,,,,,,,,,,=,,glutamate site,,, GluN2A,456,Q12879,Human,conantokin-G,4161,,16181638,NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N)CC(=O)N)CO)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@H](CC)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)CCC(=O)O)CC(C(=O)O)C(=O)O)CC(C(=O)O)C(=O)O)CC(C)C)CCC(=O)N)CC(C(=O)O)C(=O)O)CC(=O)N)CCC(=O)N)CC(C(=O)O)C(=O)O)CC(C)C)CCCNC(=N)N)CC(C(=O)O)C(=O)O,"InChI=1S/C88H138N26O44/c1-7-34(6)61(77(138)103-41(12-10-20-98-88(96)97)63(124)107-48(23-35(78(139)140)79(141)142)69(130)100-40(11-8-9-19-89)64(125)113-54(31-115)76(137)104-45(62(95)123)28-57(93)118)114-75(136)47(22-33(4)5)106-70(131)49(24-36(80(143)144)81(145)146)109-67(128)44(14-17-56(92)117)102-74(135)53(29-58(94)119)112-73(134)51(26-38(84(151)152)85(153)154)110-66(127)43(13-16-55(91)116)101-68(129)46(21-32(2)3)105-71(132)52(27-39(86(155)156)87(157)158)111-72(133)50(25-37(82(147)148)83(149)150)108-65(126)42(15-18-60(121)122)99-59(120)30-90/h32-54,61,115H,7-31,89-90H2,1-6H3,(H2,91,116)(H2,92,117)(H2,93,118)(H2,94,119)(H2,95,123)(H,99,120)(H,100,130)(H,101,129)(H,102,135)(H,103,138)(H,104,137)(H,105,132)(H,106,131)(H,107,124)(H,108,126)(H,109,128)(H,110,127)(H,111,133)(H,112,134)(H,113,125)(H,114,136)(H,121,122)(H,139,140)(H,141,142)(H,143,144)(H,145,146)(H,147,148)(H,149,150)(H,151,152)(H,153,154)(H,155,156)(H,157,158)(H4,96,97,98)/t34-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,61-/m0/s1",HTBKFGWATIYCSF-QGXIKSNHSA-N,Antagonist,Antagonist,GluN2B > GluN2D = GluN2C = GluN2A,,,,,,,,,,,,=,,glutamate site,,, GluN2A,456,Q12879,Human,d-AP5,4168,,24794417,OC(=O)[C@@H](CCCP(=O)(O)[O-])N,"InChI=1S/C5H12NO5P/c6-4(5(7)8)2-1-3-12(9,10)11/h4H,1-3,6H2,(H,7,8)(H2,9,10,11)/p-1/t4-/m1/s1",VOROEQBFPPIACJ-SCSAIBSYSA-M,Antagonist,Antagonist,,,,,,,,,,,,,=,,glutamate site,,, GluN2A,456,Q12879,Human,d-CCPene,4170,,6437356,OC(=O)C1NCCN(C1)C/C=C/P(=O)(O)O,"InChI=1S/C8H15N2O5P/c11-8(12)7-6-10(4-2-9-7)3-1-5-16(13,14)15/h1,5,7,9H,2-4,6H2,(H,11,12)(H2,13,14,15)/b5-1+",VZXMZMJSGLFKQI-ORCRQEGFSA-N,Antagonist,Antagonist,GluN2A = GluN2B > GluN2C = GluN2D,,,,,,,,,,,,=,,glutamate site,,, GluN2A,456,Q12879,Human,D-serine,4171,,71077,OC[C@H](C(=O)O)N,"InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m1/s1",MTCFGRXMJLQNBG-UWTATZPHSA-N,Agonist,Agonist,GluN2D > GluN2C > GluN2B > GluN2A,yes,,,,,,,,,,,=,,glycine site,,, GluN2A,456,Q12879,Human,GV196771A,4208,,21202952,Clc1cc(Cl)c2c(c1)[nH]c(c2/C=C/1\CCN(C1=O)c1ccccc1)C(=O)[O-],"InChI=1S/C20H14Cl2N2O3/c21-12-9-15(22)17-14(18(20(26)27)23-16(17)10-12)8-11-6-7-24(19(11)25)13-4-2-1-3-5-13/h1-5,8-10,23H,6-7H2,(H,26,27)/p-1/b11-8+",VDIRQCDDCGAGET-DHZHZOJOSA-M,Antagonist,Antagonist,,,,,,,,,,,,,=,,glycine site,,, GluN2A,456,Q12879,Human,homoquinolinic acid,4216,,3080554,OC(=O)Cc1cccnc1C(=O)O,"InChI=1S/C8H7NO4/c10-6(11)4-5-2-1-3-9-7(5)8(12)13/h1-3H,4H2,(H,10,11)(H,12,13)",HQPMJFFEXJELOQ-UHFFFAOYSA-N,Agonist,Full agonist,GluN2B ≥ GluN2A ≥ GluN2D > GluN2C; partial agonist at GluN2A and GluN2C,,,,,,,,,,,,=,,glutamate site,,, GluN2A,456,Q12879,Human,ketamine,4233,,3821,CNC1(CCCCC1=O)c1ccccc1Cl,"InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3",YQEZLKZALYSWHR-UHFFFAOYSA-N,Channel blocker,None,,,yes,,,,,,,,,,=,,,,, GluN2A,456,Q12879,Human,L689560,4239,,121918,O=C(N[C@@H]1C[C@H](Nc2c1c(Cl)cc(c2)Cl)C(=O)O)Nc1ccccc1,"InChI=1S/C17H15Cl2N3O3/c18-9-6-11(19)15-12(7-9)21-14(16(23)24)8-13(15)22-17(25)20-10-4-2-1-3-5-10/h1-7,13-14,21H,8H2,(H,23,24)(H2,20,22,25)/t13-,14+/m1/s1",UCKHICKHGAOGAP-KGLIPLIRSA-N,Antagonist,Antagonist,,,,,,,,,,,,,=,,glycine site,,, GluN2A,456,Q12879,Human,L701324,4240,,54682505,Clc1ccc2c(c1)[nH]c(c(c2=O)c1cccc(c1)Oc1ccccc1)O,"InChI=1S/C21H14ClNO3/c22-14-9-10-17-18(12-14)23-21(25)19(20(17)24)13-5-4-8-16(11-13)26-15-6-2-1-3-7-15/h1-12H,(H2,23,24,25)",FLVRDMUHUXVRET-UHFFFAOYSA-N,Antagonist,Antagonist,,,,,,,,,,,,,=,,glycine site,,, GluN2A,456,Q12879,Human,LY233053,4243,,3035974,OC(=O)[C@@H]1NCC[C@@H](C1)Cc1nnn[nH]1,"InChI=1S/C8H13N5O2/c14-8(15)6-3-5(1-2-9-6)4-7-10-12-13-11-7/h5-6,9H,1-4H2,(H,14,15)(H,10,11,12,13)/t5-,6+/m0/s1",FAAVTENFCLADRE-NTSWFWBYSA-N,Antagonist,Antagonist,,,,,,,,,,,,,=,,glutamate site,,, GluN2A,456,Q12879,Human,N1-dansyl-spermine,4260,,9889212,NCCCNCCCCNCCCNS(=O)(=O)c1cccc2c1cccc2N(C)C,"InChI=1S/C22H37N5O2S/c1-27(2)21-11-5-10-20-19(21)9-6-12-22(20)30(28,29)26-18-8-17-25-15-4-3-14-24-16-7-13-23/h5-6,9-12,24-26H,3-4,7-8,13-18,23H2,1-2H3",NSUSGNAFCIMCDH-UHFFFAOYSA-N,Channel blocker,None,GluN2A = GluN2B >> GluN2C = GluN2D,,,,,,,,,,,,=,,,,, GluN2A,456,Q12879,Human,NMDA,4268,,22880,CN[C@@H](C(=O)O)CC(=O)O,"InChI=1S/C5H9NO4/c1-6-3(5(9)10)2-4(7)8/h3,6H,2H2,1H3,(H,7,8)(H,9,10)/t3-/m1/s1",HOKKHZGPKSLGJE-GSVOUGTGSA-N,Agonist,Full agonist,GluN2D > GluN2C > GluN2B > GluN2A,,,,,,,,,,,,=,,glutamate site,,, GluN2A,456,Q12879,Human,NVP-AAM077,4276,,73755088,Brc1ccc(cc1)[C@@H](N[C@@H](P(=O)(O)O)c1cccc2c1[nH]c(=O)c(=O)[nH]2)C,"InChI=1S/C17H17BrN3O5P/c1-9(10-5-7-11(18)8-6-10)19-17(27(24,25)26)12-3-2-4-13-14(12)21-16(23)15(22)20-13/h2-9,17,19H,1H3,(H,20,22)(H,21,23)(H2,24,25,26)/t9-,17-/m0/s1",XXZGNAZRWCBSBK-XYZCENFISA-N,Antagonist,Antagonist,"GluN2A > GluN2B (human), but weakly selective for rat GluN2A versus GluN2B",,,,,,,,,,,,=,,glutamate site,,11909726|14718249|16778008|16452656, GluN2A,456,Q12879,Human,phencyclidine,4282,,6468,C1CCC(CC1)(N1CCCCC1)c1ccccc1,"InChI=1S/C17H25N/c1-4-10-16(11-5-1)17(12-6-2-7-13-17)18-14-8-3-9-15-18/h1,4-5,10-11H,2-3,6-9,12-15H2",JTJMJGYZQZDUJJ-UHFFFAOYSA-N,Channel blocker,None,,,,,,,,,,,,,=,,,,, GluN2A,456,Q12879,Human,UBP141,4332,,9864550,O=C(N1CCN[C@@H]([C@@H]1C(=O)O)C(=O)O)c1ccc2c(c1)c1ccccc1cc2,"InChI=1S/C21H18N2O5/c24-19(23-10-9-22-17(20(25)26)18(23)21(27)28)14-8-7-13-6-5-12-3-1-2-4-15(12)16(13)11-14/h1-8,11,17-18,22H,9-10H2,(H,25,26)(H,27,28)/t17-,18+/m0/s1",VVUAQPXBYDYTDF-ZWKOTPCHSA-N,Antagonist,Antagonist,GluN2D ≥ GluN2C > GluN2A ≥ GluN2B,,,,,,,,,,,,=,,glutamate site,,15801853, GluN2A,456,Q12879,Human,D-aspartic acid,6511,,83887,OC(=O)C[C@H](C(=O)O)N,"InChI=1S/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)/t2-/m1/s1",CKLJMWTZIZZHCS-UWTATZPHSA-N,Agonist,Agonist,GluN2D > GluN2C = GluN2B > GluN2A,yes,,,,,,,,,,,=,,glutamate site,,, GluN2A,456,Q12879,Human,TCN-201,7846,,4787937,O=C(c1ccc(cc1)CNS(=O)(=O)c1ccc(c(c1)Cl)F)NNC(=O)c1ccccc1,"InChI=1S/C21H17ClFN3O4S/c22-18-12-17(10-11-19(18)23)31(29,30)24-13-14-6-8-16(9-7-14)21(28)26-25-20(27)15-4-2-1-3-5-15/h1-12,24H,13H2,(H,25,27)(H,26,28)",FYIBXBFDXNPBSF-UHFFFAOYSA-N,Allosteric modulator,Negative,,,yes,,pIC50,,7.0,,IC50,,100.0,,=,Inhibition of glycine-induced (1µM) NMDA receptor responses measured in Xenopus oocytes co-expressing hGluN1 and hGluN2A NMDA receptor subunits,,,22553026, GluN2A,456,Q12879,Human,NYX-2925,11289,,122594417,CC(C(=O)N1CCC[C@@]21CN(C2=O)[C@H](C(=O)N)[C@H](O)C)C,"InChI=1S/C14H23N3O4/c1-8(2)12(20)17-6-4-5-14(17)7-16(13(14)21)10(9(3)18)11(15)19/h8-10,18H,4-7H2,1-3H3,(H2,15,19)/t9-,10+,14-/m1/s1",NFXPEHLDVKVVKA-ISTVAULSSA-N,Allosteric modulator,Positive,,,,,pEC50,,10.26,,EC50,,0.055,,=,Potentiation of glycine site agonist MK-801 binding to human N-methyl-D-aspartate receptor NR2A-D subtypes expressed in HEK cells.,,,29099938, GluN2A,456,Q00959,Rat,TCN-213,11700,,2608149,C1CCC(CC1)CNC(=O)CSc1nnc(s1)NCc1ccccc1,"InChI=1S/C18H24N4OS2/c23-16(19-11-14-7-3-1-4-8-14)13-24-18-22-21-17(25-18)20-12-15-9-5-2-6-10-15/h2,5-6,9-10,14H,1,3-4,7-8,11-13H2,(H,19,23)(H,20,21)",XBAZPYFIYYCZBO-UHFFFAOYSA-N,Allosteric modulator,Negative,,,,,pIC50,,6.26,,IC50,,550.0,,=,Inhibition of glycine-induced activation of GluN1/GluN2A NMDA channels in vitro,,,22022974, GluN2A,456,Q12879,Human,SAGE-718,12050,,86305217,C[C@H](CC[C@@](C)(C(F)(F)F)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]1[C@H]2CC=C2[C@@]1(CC[C@](C2)(C)O)C)C,"InChI=1S/C27H43F3O2/c1-17(10-13-26(5,32)27(28,29)30)20-8-9-21-19-7-6-18-16-23(2,31)14-15-24(18,3)22(19)11-12-25(20,21)4/h6,17,19-22,31-32H,7-16H2,1-5H3/t17-,19+,20-,21+,22+,23+,24+,25-,26+/m1/s1",BVBRUQYHUXKZMQ-JNVAYQLDSA-N,Allosteric modulator,Positive,,,,,pEC50,,7.07,,EC50,,86.0,,=,Value obtained using automated patch clamp electrophysiology in HEK293 cells stably expressing recombinant human GluN1/GluN2A Rs,,,35785990, GluN2A,456,Q12879,Human,plazinemdor,12051,,146315728,CC1(CN(C1)C(=O)Cn1cnc2c(c1=O)c(cn2C1CC1)c1cc(c(cc1)F)Cl)F,"InChI=1S/C21H19ClF2N4O2/c1-21(24)9-27(10-21)17(29)8-26-11-25-19-18(20(26)30)14(7-28(19)13-3-4-13)12-2-5-16(23)15(22)6-12/h2,5-7,11,13H,3-4,8-10H2,1H3",NULHGWQIRTXKAY-UHFFFAOYSA-N,Allosteric modulator,Positive,,,,,pEC50,,6.36,,EC50,,439.0,,=,Determined in a 2-electrode voltage clamp system using oocytes expressing hNR2A and activated with glutamate and glycine.,,,,